INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 222 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2019. The put-call ratio across all filers is 1.18 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $32,394,000 | -21.8% | 781,325 | -9.6% | 1.84% | -28.9% |
| Q2 2020 | $41,411,000 | -39.0% | 864,345 | -19.8% | 2.58% | -67.5% |
| Q1 2020 | $67,889,000 | -55.1% | 1,078,291 | -11.6% | 7.95% | -22.6% |
| Q4 2019 | $151,073,000 | +94.4% | 1,219,121 | +4.1% | 10.27% | +53.3% |
| Q3 2019 | $77,702,000 | -4.9% | 1,170,910 | +14.1% | 6.70% | -6.5% |
| Q2 2019 | $81,670,000 | +10.3% | 1,026,388 | +55.0% | 7.17% | +28.9% |
| Q1 2019 | $74,074,000 | -9.6% | 662,200 | -32.2% | 5.56% | -1.6% |
| Q2 2018 | $81,907,000 | +15.6% | 976,127 | -15.3% | 5.65% | +4.6% |
| Q1 2018 | $70,873,000 | +25.0% | 1,152,032 | +18.7% | 5.40% | +35.0% |
| Q4 2017 | $56,721,000 | +67.4% | 970,926 | +66.3% | 4.00% | +79.1% |
| Q3 2017 | $33,883,000 | – | 583,790 | – | 2.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $14,787,000 | 2.73% |
| DeepCurrents Investment Group LLC | 416,800 | $9,620,000 | 0.33% |
| DUALITY ADVISERS, LP | 105,668 | $2,439,000 | 0.21% |
| EULAV Asset Management | 335,000 | $7,732,000 | 0.21% |
| Virtus ETF Advisers LLC | 19,375 | $447,000 | 0.19% |
| Hennion & Walsh Asset Management, Inc. | 135,214 | $3,121,000 | 0.19% |
| PDT Partners, LLC | 110,592 | $2,552,000 | 0.18% |
| KETTLE HILL CAPITAL MANAGEMENT, LLC | 70,256 | $1,622,000 | 0.16% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $3,896,000 | 0.12% |
| WOODWARD DIVERSIFIED CAPITAL, LLC | 8,939 | $206,000 | 0.12% |